Reports Q4 revenue $3.89B, consensus $3.77B. "Baxter employees worldwide are embracing the power of our lifesaving Mission to navigate a complex healthcare landscape and respond to sustained demand for our essential products," said Jose (Joe) E. Almeida, chairman, president and chief executive officer. "Ongoing macroeconomic challenges and supply chain headwinds continue to weigh on business performance, underscoring the need for decisive action to create value for the patients, shareholders and other stakeholder communities that rely on us. I am confident that the plans we announced last month to spin off a new kidney care company and implement a new operating model for our remaining businesses will enhance the potential for growth and innovation across both entities."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BAX:
- Baxter Crumbles as Projections Disappoint, Job Cuts Planned
- Notable companies reporting before tomorrow’s open
- Baxter price target lowered to $60 from $73 at KeyBanc
- Miromatrix MiroliverELAP timeline pushed out two or three quarters, says Piper
- Miromatrix Medical, Baxter enter research agreement for ALF
